Cellceutix Receives FDA Orphan Drug Designation for Kevetrin for the Treatment of Pancreatic Cancer
January 21, 2016 11:47 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - January 21, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix Submits Briefing Book for Phase 2 Trial of p53 Targeting Drug for Ovarian Cancer
January 19, 2016 08:00 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - January 19, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Brilacidin Lyophilized as Cellceutix Prepares to Bring First New Class of Antibiotic to Phase 3 Trials in More Than 20 Years
January 14, 2016 10:13 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - January 14, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix Invites All to Attend Its Live Webcast of Company's Presentation at Biotech Showcase 2016
January 05, 2016 15:54 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - January 05, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix Stockholders Tour Company Facilities at First Annual Stockholder Meeting; Investors Express Support for Company and Disgust for Seeking Alpha Article
December 17, 2015 11:15 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - December 17, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix First Annual Shareholder Meeting December 15, 2015
December 14, 2015 07:30 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - December 14, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix Completes Lab Testing of Brilacidin for Planned Phase 3 Trial for Acute Bacterial Skin and Skin Structure Infections
December 11, 2015 09:18 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - December 11, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix Receives Rare Pediatric Disease Designation From FDA for Kevetrin for the Treatment of Retinoblastoma
December 01, 2015 10:31 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - December 01, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix Retains Former Durata Executive Ronald Trust as Regulatory Affairs Consultant
November 30, 2015 07:30 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - November 30, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
FDA Grants Fast Track Designation to Cellceutix's Brilacidin-OM for Oral Mucositis
November 25, 2015 08:00 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - November 25, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...